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Abstract 
 
Respiratory syncytial virus (RSV) infects most children in the first year of life and is a 
major single cause of hospitalization in infants and young children. There is no 
effective vaccine, and antibody generated by primary neonatal infection is poorly 
protective against re-infection even with antigenically homologous viral strains. 
Studying the immunological basis of these observations in neonatal mice, we found 
that antibody responses to infection were low and unaffected by CD4 depletion, in 
contrast with adult mice, which had stronger CD4 dependent antibody responses. NK 
cell depletion or co-depletion of CD4+ and CD8+ cells during neonatal RSV infection 
caused a striking increase in anti-RSV antibody titer. These cells are major sources of 
the cytokine interferon gamma (IFN-γ), and blocking IFN-γ also enhanced RSV 
specific antibody responses in neonates. In addition, infection with a recombinant 
RSV engineered to produce IFN-γ reduced antibody titer, confirming that IFN-γ plays 
a pivotal role in inhibition of antibody responses after neonatal infection. These 
unexpected findings show that the induction of a strong cellular immune response 
may limit antibody responses in early life and that vaccines which induce IFN-γ 
secreting cells might, in some situations, be less protective than those that do not. 
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Introduction 
 
Antibody responses to vaccines are poor in infancy (1) and this can lead to increased 
infection severity and decreased vaccination efficacy. It is believed that the paucity of 
the infantile antibody response is caused by immaturity of the cells involved (2, 3). 
Neonatal B cells are immature, expressing lower levels of MHC-II (4) and when B 
cells are transferred from adult mice into the footpads of neonates the antibody 
response is restored to adult levels (5). In addition to poor B and T cell interactions, 
the development of follicular dendritic cells is delayed in both neonatal mice (6) and 
infants (7). Improved understanding about B cell responses is required to improve 
early life vaccine strategies, particularly in the control of respiratory infections, which 
are a major cause of morbidity and mortality in infancy. 
 
Respiratory syncytial virus (RSV) is the principal cause of viral lung infection in 
infants (8). Hospitalization rates due to RSV bronchiolitis in the USA are 17 per 1,000 
children below 6 months of age (9), with an estimated 33.8 million cases of RSV 
associated lower respiratory tract infection and 66,000-199,000 deaths globally per 
annum (10). Re-infection is common and does not necessarily depend on antigenic 
changes (11), 47% of children infected in the first year of life are re-infected in their 
second year of life (12). An effective RSV vaccine would be a major breakthrough in 
child health and since most children with RSV bronchiolitis are under 6 months of 
age, it would need to be effective in infancy. A core component of protection against 
RSV infection is antibody – high-titer, maternally-derived, RSV-neutralizing antibody 
is protective against hospitalization (13) and protection against re-infection in humans 
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is associated with high titers of antibody (14). Antibody responses seen in infants after 
both RSV infection (15, 16) and vaccination (17, 18) are weak, an effect usually 
attributed to reduced T cell help. Few CD4 T cell lymphocytes are found in the lungs 
of RSV infected infants (19) and the V gene repertoire for anti-RSV antibody is 
restricted in neonatal humans (20). We have developed a mouse model of neonatal 
RSV infection (21) where we observed that infection of neonatal mice led to a T cell 
response that caused disease on subsequent re-infection (22). Furthermore, we 
subsequently showed that this pathogenic cellular response is dependent upon the 
mouse MHC haplotype (23). 
 
Antibody titers are lower following experimental neonatal mouse RSV infection 
compared to adult infection (24). Studying the basis of these observations, we wished 
to assess whether the cellular response to neonatal RSV affected the antibody titer. 
We found that CD4+ cell depletion did not reduce neonatal antibody titers, but 
depleting natural killer (NK) cells or CD4+ and CD8+ cells together increased 
antibody titer. During neonatal RSV infection, NK and T cells produced the cytokine 
IFN-γ, which has been shown to inhibit the antibody response (25). When IFN-γ was 
depleted during neonatal RSV infection, the antibody titer significantly increased. 
This novel demonstration of the inhibition of antibody production by the cellular 
response during neonatal infection has important implications for the control of RSV 
in early life. 
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Results 
Reduced antibody response in neonates compared to adults after RSV infection. 
BALB/c mice were infected with 4x104 PFU/g body weight RSV at either 4 days 
(neonatal; 105 PFU) or 28 days (adult; 106 PFU) of life (schematic of experimental 
protocol in Figure 1A). Mice infected as neonates had significantly lower viral loads 
than adults on day 4 post primary infection (Fig 1B, p<0.01), as previously observed 
(21, 26). Serum was collected 8 weeks after primary infection to allow maturation of 
responses. Sera from mice that had primary RSV infection as adults had significantly 
more RSV-specific ELISA binding (Fig 1C, p<0.001) and neutralizing (Fig 1D, 
p<0.001) antibody than mice that had a primary infection as neonates. RSV-specific 
IgG subtypes were quantified by ELISA in sera. The neonatal RSV-IgG response was 
significantly skewed towards IgG1 (indicating a Th2 bias; p<0.001), whilst adult 
primary infection led to a balanced IgG1/IgG2a response (Fig S1A). 
 
Mice were re-infected with 106 PFU of the same RSV strain 8 weeks after their initial 
infection (Fig 1A). Previous exposure to RSV, regardless of age, significantly reduced 
viral load during secondary RSV infection, compared to primary RSV infection (Fig 
1B, p<0.01). But mice that were primed as adults had a significantly reduced viral 
load than mice primed as neonates (p<0.05). Whilst re-infection significantly boosted 
antibody titers in both neonatally and adult primed mice (Fig 1C, p<0.001), adult 
primed mice still had significantly greater antibody titers (Fig 1C, p<0.001) and more 
potent neutralizing responses (Fig 1D, p<0.001) than neonatally primed mice after re-
infection. Adult re-infection of neonatally primed mice reversed the initial IgG1 bias, 
leading to a predominantly IgG2a response (Fig S1B). Neonatal mice generated 
weaker antibody responses to RSV infection, which may reduce protection against 
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subsequent viral re-exposure and contribute to the delayed sequelae of neonatal RSV 
infection (22). 
 
T cells and NK cells inhibit the neonatal antibody response. 
We have previously observed that depletion of T cells during neonatal RSV infection 
can have a protective effect during re-infection (22). To assess their effect on antibody 
responses, T cells were depleted during primary neonatal RSV infection and antibody 
responses measured before and after re-infection (schematic in Fig 1A). Cell depletion 
significantly reduced the targeted cell type (Fig S2). CD4+ cell depletion had no effect 
on the weak anti-RSV antibody response in neonates after primary (Fig 2A) or 
secondary infection (Fig 2B). However, depletion of both CD4+ and CD8+ cells 
together significantly boosted IgG after primary (p<0.001) and secondary (p<0.05) 
RSV infection. Depletion of CD4+ cells during primary adult RSV infection did not 
significantly change the antibody titer before re-infection (Fig 2C) but caused a 
significant reduction in anti-RSV IgG titer after re-infection (Fig 2D, p<0.05), as 
previously observed (27). CD4 and CD8 co-depletion during primary adult RSV 
infection had no effect on IgG titer (Fig 2D). To define the timing of the effect, T cells 
were depleted during secondary RSV infection of neonatally primed mice. When T 
cells were depleted during secondary RSV infection of neonatally primed mice, CD8+ 
cell depletion made no effect on antibody titer, but CD4+ cell depletion or depletion of 
both CD4+ and CD8+ cells together significantly reduced the titer (Fig 2E, p<0.01). In 
addition, cell depletion during primary neonatal infection increased levels of IgG1 
compared to control neonatal infection (Fig S1C-D). 
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To test whether NK cells also affected the neonatal antibody response, we depleted 
NK cells with anti-asialo GM1 during primary neonatal RSV infection. NK cell 
depletion had no effect on antibody titer before re-infection (Fig 2F). However, NK 
cell depleted neonatal mice had significantly higher anti-RSV IgG responses than 
untreated mice after re-infection (Fig 2G, p<0.05). Suppression of antibody responses 
by NK cells has been previously observed (28) and was linked to inhibition of antigen 
presenting cells (29). This suppression may be caused by NK cell killing the antigen 
presenting cells using the FasL pathway. To test this, antibody responses to RSV 
infection were measured in FasL-/- deficient (gld) mice. The FasL-/- mice are on a 
C57BL/6 background so we confirmed that cell depletion affected antibody levels in 
C57BL/6 mice (Fig 2H). Neonatal CD4+ cell depletion had no effect, but CD8+ cell 
depletion significantly increased RSV-specific antibody titer (p<0.05). When levels 
were compared, there was no significant difference in antibody titer between the wild 
type and FasL-/- deficient mice (Fig 2I). 
 
Interferon gamma inhibits the neonatal antibody response. 
The lower viral load during primary neonatal infection may contribute to the reduced 
neonatal antibody responses. RSV viral titer was measured on day 4 after primary 
neonatal infection with and without cell depletion (Fig 3A). As previously 
demonstrated (30), NK depletion significantly increased viral load (p<0.05). 
However, T cell depletion had no effect on viral load, suggesting that increased viral 
load does not account for the increased antibody titer after T cell depletion. To further 
address the role of viral load on antibody response, neonatal mice were infected with 
different doses of virus (1.2x104 PFU, 5.5x104 PFU and 2.6x105 PFU). There was no 
apparent difference in antibody responses between groups after secondary infection 
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(Fig 3B). Likewise there was no difference in antibody titer when adult mice (Fig 3C) 
were infected with different primary doses of virus (8.0x104 PFU or 5.0x105 PFU). 
These data suggest that the increased antibody titer seen after cell depletion is not 
caused by differences in viral load. 
 
IFN-γ has been shown to have an inhibitory effect on antibody responses (25). In 
previous studies, we observed that neonatal mice infected with recombinant RSV 
expressing IFN-γ have reduced antibody responses (31). Whilst, there is a well 
described Th2 bias in neonatal life (3), we and others, have shown that there are RSV 
specific IFN-γ secreting CD8 cells following neonatal RSV infection (22, 32). Mice 
were infected at day 4 of life and cytokine levels measured in lung homogenate 
supernatants at various time points after infection. RSV infected mice had 
significantly more IFN-γ in the lungs at days 1 and 7 post infection than naïve 
littermate controls (Fig 3D, p<0.01). IFN-γ levels increased in the lungs with age in 
both naive and infected mice, which may reflect increased immunological maturity or 
the increased size of the lungs. To define which cells produced IFN-γ, cells were 
isolated during primary infection and stimulated with PMA/ionomycin. Infected mice 
had significantly more IFN-γ producing NK cells on day 1 post infection (day 5 of 
life) compared to age matched controls (Fig 3E, p<0.05). A significant increase in 
IFN-γ producing CD8 cells was observed on days 7 and 11 post infection (Fig 3F, 
p<0.05) and CD4 cells on day 11 post infection (Fig 3G, p<0.001). To determine 
whether cell depletion affected IFN-γ production, levels were measured in lung 
homogenates on day 4 after neonatal infection with and without cell depletion (Fig 
3H). Reduced levels were seen in the anti-CD4 and CD8 double depletion group and 
the anti-NK group. 
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We next investigated whether IFN-γ might have an inhibitory effect on antibody 
responses. Neonatal mice were infected with RSV and IFN-γ was blocked using three 
doses of anti-IFN-γ (clone XMG1.2) i.p. on days -1, +2 and +5. Blocking IFN-γ 
during primary infection significantly boosted antibody prior to (Fig 4A, p<0.05) and 
after (Fig 4B, p<0.001) re-infection. IFN-γ blockade lead to a more balanced 
IgG1:IgG2a ratio than control treatment (Fig S1E, p<0.05). To confirm that the IFN-γ 
was affecting the antibody response we used a recombinant RSV that expressed IFN-γ 
(33). As we have observed previously (31), there was no effect on antibody titer prior 
to rechallenge (Fig 4C), but after rechallenge with wild type virus, the antibody 
response in the rRSV-IFN-γ primed animals was significantly lower than wild type 
RSV primed mice (Fig 4D, p<0.001). Infection with rRSV-IFN-γ significantly 
reduced the IgG1 response (Fig S1F, p<0.05). To support the argument that increases 
in antibody responses are independent of viral load, mice treated with anti-IFN-γ had 
significantly lower viral loads during primary neonatal infection than control treated 
mice but greater antibody responses (Fig 4E, p<0.001). As previously observed (31) 
the rRSV-IFN-γ infected mice had a significantly lower viral titer than control 
infected neonatal mice (p<0.05). We therefore conclude that neonatal anti-RSV 
antibody responses are inhibited by the cellular immune response, and that IFN-γ 
plays a vital role in this inhibition. 
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Discussion 
  
The antibody response following neonatal RSV infection was lower than the adult 
response. Cellular depletion (CD4, CD8 or NK) during primary neonatal infection 
significantly increased the antibody response. These cells all produced IFN-γ during 
neonatal infection and if IFN-γ was blocked the antibody response was significantly 
enhanced. The absence of effect of neonatal CD4+ cell depletion suggests that 
neonatal B cells have a reduced requirement for CD4 help and that possibly the early 
life antibody response to RSV is T cell independent, unlike the adult response. This 
would fit with the observation that the neonatal anti-RSV response has reduced 
somatic hypermutation (20) and that there are reduced numbers of T follicular helper 
cells (Tfh) in neonates (34). Levels of the TNF family receptors critical for the 
development and maintenance of B cells (BAFF-R, BCMA and TACI) have been 
demonstrated to be lower in cord blood (35) and neonatal mice (36). Whilst germinal 
centers are immature in early life (6), adjuvants that induce maturation of follicular 
dendritic cells can restore antibody levels (37). While we did not directly address the 
role of IFN-γ on antibody response in adult mice, we did observe that they have CD4 
dependent antibody responses to RSV infection (Fig 2D). In addition we have 
previously shown that there is a significantly greater RSV specific IFN-γ response in 
adult mice than neonatal mice (22). This suggests that the absence of strong CD4: B 
cell interactions in neonates contributes to the suppression of the antibody response by 
IFN-γ.  
 
Inhibition of antibody by IFN-γ has been observed in other systems, IFN-γ receptor 
deficient mice have enhanced antibody responses to Bordetella pertussis infection 
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(38) and STAT1 receptor deficient mice have enhanced antibody responses to RSV 
infection (39). This inhibitory role for IFN-γ in the neonatal immune response is 
surprising because of the reported Th2 skew of responses, but Th1 responses can be 
observed in human neonates for example to BCG (40) and in mice can be boosted by 
the addition of TLR ligands (41). There are several mechanisms by which IFN-γ 
might inhibit the antibody response. It is possible that the cell and cytokine 
manipulations increased the viral load, thereby increasing the antigen exposure. 
However, multiple strands of evidence suggest that antibody titer is not solely 
influenced by viral load: depleting neonatal T cells had no effect on viral load (Fig 
3A), anti-IFN-γ treatment decreased viral load (Fig 4E), the rRSV-IFN-γ virus was 
significantly attenuated as previously observed (33, 42) and when neonatal or adult 
mice were infected with different amounts of virus, there was no effect on antibody 
response (Fig 3B, C). The decrease in viral load after neonatal anti-IFN-γ treatment 
was in contrast to adult mice, which either had unchanged (43) or increased (44) viral 
load after anti-IFN-γ treatment. The decreased viral titer after neonatal anti-IFN-γ 
treatment may suggest that removing the suppression of antibody response by IFN-γ 
also has an effect on the viral load. From our studies we cannot rule out the role of 
other effectors or cells in the inhibition of the neonatal antibody response, but believe 
that during neonatal RSV infection, NK and T cells produce IFN-γ, which acts on 
cells important for the generation of antibody inhibiting their function, for example B 
cells (25, 45, 46).  
 
The cell depletion experiments, reported in the current study, do not distinguish 
between cells producing IFN-γ or cells responding to IFN-γ and the effect on antibody 
response. Possible targets for IFN-γ include NK cells, T cells and B cells and further 
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studies are required to identify which plays a role. Co-depletion of NK and T cells 
together did not further increase the antibody titer over single cell type depletion. 
Since NK cells have been described as limiting antibody by inhibiting APC (29), it 
may be that the T cells generate the IFN-γ in response to the viral infection, activating 
the NK cells leading to APC inhibition. However, we observed no difference in FasL-
/- deficient mice, suggesting the inhibitory mechanism is independent of this pathway. 
It may be that other killing mechanisms or cell types are involved (47), for example 
Treg cells, which utilize granzyme B to resolve inflammation after RSV infection (48) 
or CD8 cells, which have been shown to kill LCMV infected B cells (49). CD8 T cells 
have been shown to downregulate the Th2 CD4 T cell response to RSV (50) and 
transferring RSV specific CD8 cells into adult mice has an inhibitory effect on 
antibody responses (51). However, this does not explain why CD4 and CD8 co-
depletion enhanced antibody responses. Neonatal B cells have been shown to have 
reduced expression of IL-4 receptor, which may potentiate the inhibitory effects of 
IFN-γ (52). While IFN-γ has been shown to inhibit IL-4 and thereby reduce classical 
Th2 help for B cells, the effect of IFN-γ on other CD4 helper subsets which may play 
a role, such as T follicular help, is not well characterized, recently IL-21 depletion has 
been shown to reduce anti-RSV antibody (53).  
 
The effect of IFN-γ on the anti-RSV antibody response in early life may go some way 
to explain why infants can be re-infected with the same virus in the same or 
consecutive seasons. We have not succeeded in our attempts to determine how general 
our observations are and so are unable to say whether this is an RSV specific effect. 
The inhibition of antibody responses by the cellular response may have an impact on 
the development of RSV vaccines for use in early life. If vaccines induce a strong 
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cellular response producing IFN-γ, it may reduce the anti-RSV antibody response. By 
understanding the effect of IFN-γ on antibody responses we can optimize pediatric 
vaccine formulations and schedules to minimize the inhibitory effects. 
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Methods 
Mice and Virus. Time mated pregnant BALB/c or C57BL/6 mice (Harlan, Bevil’s 
Hill, UK) were purchased at <14d gestation and pups were weaned at 3wk old. Mice 
were infected i.n. with 4x104 PFU/gram body weight RSV A2 at 4 days (neonatal ~ 
105 PFU in 20μl) or 4-6 weeks of age (adults ~ 5 x 105 PFU in 100μl) under 
isofluorane anesthesia. Mice were re-infected i.n. 8 weeks later, with 106 PFU RSV in 
100µl. Recombinant RSV expressing IFN-γ (rRSV-IFN-γ) was obtained from Dr 
Peter Collins and was generated as described previously (33). Breeding pairs of Fas 
ligand (FasL-/-) deficient mice (gld) were obtained as a kind gift from Professor 
Anthony Warrens (Imperial College London) and the litters from these were used in 
the same protocol as the wild type mice. RSV A2 strain was grown in HEp-2 cells and 
viral titer determined by immune-plaque assay.  
 
RSV viral load was assessed by extracting RNA from lung tissue using STAT-60 or 
RNeasy mini kit (Qiagen) and then converting it into cDNA. Quantitative RT-PCR for 
the RSV L gene using primers and probes previously described, (21) was performed 
and the results normalized against 18s or GAPDH endogenous RNA levels. L gene 
copy number was determined using a RSV L gene standard and presented relative to 
μg lung RNA. 
 
For cell depletion, mice were treated with 500µl (adults) or 100µl (neonates) of 
1mg/ml antibody i.p. on d-1, d+2 and d+5 post infection. Cells were depleted using 
anti-CD4 (hybridomas YTA 191 and YTA 3), anti-CD8 (clone YTS 156) and control 
treatment used an irrelevant matched isotype control. All antibodies were IgG2b and a 
kind gift of S. Cobbold, Oxford University. IFN-γ was blocked in neonatal mice using 
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100µl of 1mg/ml antibody from clone XMG1.2 (eBioscience, UK) i.p. on d-1, d+2 
and d+5 post infection. NK cells were depleted with 100μl anti-asialo GM1 (Wako, 
Japan) on d-1 and d+2 post infection. All work was approved and licensed by the UK 
Home Office. 
 
RSV-specific antibody quantification. A quantitative assay was used to determine 
serum antibody levels adapted from Donelly et al (54). 96-well plates were coated 
with RSV antigens and blocked with 1% BSA. A dilution series of recombinant 
murine IgG was used on each plate as a standard to quantify the RSV specific 
antibodies. Sera were diluted 1:500, 1:5,000 and 1: 50,000 to ensure the absorbance 
reading measured fell within the linear range of the standard curve. Bound IgG was 
detected by incubation for 2 hr at 37 ºC with HRP-conjugated goat anti-mouse IgG 
(AbD Serotec). Plates were washed and developed with 50 μl TMB/E substrate and 
the reaction was terminated by the addition of 50 μl of 2M H2SO4 and read at A450. 
For IgG subtype measurements, a similar protocol was performed using biotinylated 
anti-IgG1 or anti-IgG2a and detected using HRP-Streptavidin, compared to a standard 
curve of recombinant murine IgG1 or IgG2a. Viral neutralization by antibody was 
assessed as described before (55).  
 
IFN-γ cytokine ELISA. Cytokine levels were assessed in lung homogenate 
supernatants by ELISA using a pair of capture and biotinylated detection antibodies 
(R&D systems) following the manufacturer’s instructions. Mediator concentrations 
were quantified by comparison to recombinant cytokine standards. 
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Cell preparation and flow cytometry. After infection, animals were culled using i.p. 
pentobarbitone. Cells were harvested as described previously (56). Prior to staining 
cells were blocked with CD16/32 (BD). For surface staining antibodies against the 
surface markers CD3 (17A2, FITC), CD4 (RM4-5, APC), CD8 (53.6-7, PerCP) and 
CD49b (DX5, PE) were added in 1:100 dilution. For intracellular staining, cells were 
stimulated for 4h at 37°C in the presence of 10 μg/ml Brefeldin A, 100μg/ml PMA 
and 10μg/ml ionomycin. Cells were permeabilised with 0.5% saponin and stained 
with directly conjugated anti-IFN-γ (XMG2.1, FITC). Samples were run on an LSR 
(BD) and analyzed using Winlist (Verity).  
 
Statistical analysis. Results are expressed as mean ± S.E.M.; statistical significance 
was calculated by ANOVA followed by Tukey tests or t tests using GraphPad Prism 
software, as indicated in figure legends.  
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Figure Legends   
 
Figure 1. Antibody responses to RSV infection in early life are less than adult 
responses. BALB/c mice were infected with 4x104 PFU RSV per gram body weight 
intranasally as neonates (age 4 days, ▪) or as immature adults (age 4-6 weeks, ●) 
(1°RSV). 8 weeks after the primary infection, mice were given a secondary infection 
of 106 PFU RSV (2° RSV). Schematic experimental protocol (A) including cellular 
depletion protocol (Ig indicates an antibody depletion time point). Lung viral load was 
measured by quantifying RSV L gene expression on day 4 of primary (1° RSV, closed 
symbols) or secondary (2° RSV, open symbols) infection (B). RSV-specific IgG (C) 
and in vitro RSV neutralization (D) measured in sera collected after primary and 
secondary infections. Points represent individual mice, lines represent mean of n≥4 
mice per group +/- SEM (A and C show pooled data from 2 experiments, B is 
representative of 2 experiments), * p<0.05, ** p<0.01, *** p<0.001, calculated using 
t-test. 
 
Figure 2. Cell depletion increases neonatal antibody response to RSV infection. 
CD4, CD8 or NK cells were depleted during primary RSV infection of neonatal (A, 
B, F, G), or adult (C, D) BALB/c mice or during secondary RSV infection of BALB/c 
mice initially infected as neonates (E). RSV-specific IgG was measured on day-1 (A, 
C, F) or day 7 (B, D, E, G) of RSV secondary infection. Wild type (wt) C57BL/6 
were infected as neonates with RSV, with or without cell depletion (H) or compared 
to FasL-/- mice (I) and serum anti-RSV IgG measured on day 7 of RSV secondary 
infection. Points represent individual mice, lines represent mean of n≥3 mice per 
group +/- SEM, * p<0.05, ** p<0.01, *** p<0.001, calculated using ANOVA and 
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post test. Data presented are pooled from 2 experiments except panels C, D which is 
from a single experiment. 
 
Figure 3. Interferon gamma is produced during neonatal RSV infection. Neonatal 
BALB/c mice were infected with 105 PFU RSV; CD4, CD8 or NK cells were depleted 
during RSV infection and lung viral load was measured by quantifying RSV L gene 
expression on day 4 post primary infection (A). Neonatal (B) and adult (C) mice were 
infected with different primary doses of RSV and RSV-specific IgG titer measured on 
day 7 after secondary RSV infection. 4 day old mice were infected with RSV (●) or 
left naïve (∆), IFN-γ was measured in lung homogenate by ELISA (D) and IFN-γ 
expression measured in PMA/ionomycin stimulated lung NK (DX5+) (E), CD8 (F) 
and CD4 (G) cells by flow cytometry. IFN-γ levels were measured in lung 
homogenate at day 4 post primary RSV infection, with and without cell depletion (H). 
Points represent individual mice, lines represent mean of n≥3 mice per group 
(A,B,C,H), bars/points represent mean of n≥4 mice per group ± SEM (D,E,F,G). Data 
shown is representative of one experimental repeat, * p<0.05, ** p<0.01, *** 
p<0.001, calculated using ANOVA and post test.  
 
Figure 4. Interferon gamma inhibits antibody responses to neonatal RSV 
infection. During primary RSV infection, neonatal BALB/c mice were treated with 
anti-IFN-γ or left untreated, 8 weeks later, mice were re-infected with RSV. RSV-
specific IgG was measured in sera on day-1 (A) and day 7 (B) of secondary infection. 
Neonatal mice were infected with recombinant RSV expressing IFN-γ (rRSV-IFN-γ) 
or wild type RSV A2, and 8 weeks later mice were re-infected with wild type RSV 
A2. RSV-specific IgG was measured in sera on day-1 (C) and day 7 (D) of secondary 
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infection. Viral load (RSV L gene) was measured during primary neonatal infection 
by RT-PCR in lungs of control mice or mice infected with RSV and treated with anti-
IFN-γ or infected with rRSV-IFN-γ (E). Points represent individual mice, lines 
represent mean of n≥4 mice per group. The data is pooled from 2 experimental 
repeats. * p<0.05, ** p<0.01, *** p<0.001, calculated using ANOVA and post test. 
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